CURRENT PRACTICE OF HYDROXYCHLOROQUINE PRESCRIPTION AND MONITORING IN INDIA - A NATIONAL SURVEY

Shilpa Jagadeesh 1, Arumugam Moorthy 2, B G. Dharmanand 2, University Hospitals Leicester, Rheumatology Registrar, Leicester, United Kingdom; 2University Hospitals Leicester, Consultant Rheumatologist, Leicester, United Kingdom; 3Vikram Hospital, Consultant Rheumatologist, Bengaluru, India

Background: Hydroxychloroquine was introduced as an antimalarial during World War 2 and since then has found numerous indications for usage as an immunomodulator. Research is ongoing for new uses of the drug. Hydroxychloroquine is generally considered to be safe and monitored less rigorously than other DMARDS that have strict bloods monitoring regimes. Emerging evidence of increased risk of retinal toxicity possibly due to widespread usage in a population with diverse co-morbidity has prompted updates to prescription and monitoring guidelines worldwide.

Objectives:
2. Understand awareness of cross specialty guidelines.
3. Explore barriers to evidence based monitoring.

Methods: Questionnaire based survey shared to practicing clinicians (consultant rheumatologists, Immunologists, postgraduate trainees, other clinicians with interest in rheumatology) who prescribe Hydroxychloroquine. Results analyzed through excel spreadsheet and charts.

Results: We received 61 responses from clinicians nationally. 88.5% were consultant rheumatologists, 6.6% consultant immunologists and others included clinicians with interest in rheumatology. Special interest was CTD for 47.5% and 36% inflammatory arthritis. All respondents worked in urban areas and average experience in specialty was 9 years. Majority saw in excess of 500 patients month. 61 clinicians saw in excess of 24,700 patients per month and on average started more than 2481 patients on Hydroxychloroquine. Approximate prescription rate was 41 patients per clinician per month. Indications included connective tissue disease and inflammatory arthritis mainly. Other indications include ankylosing spondylitis, osteoarthritis, post viral arthropathy, dermatomyositis and diabetic arthropathy. Pretreatment tests as per international guidelines were recommended by 35% clinicians only which includes baseline Optical coherence tomography 25%, or eye evaluation by ophthalmologist 10%. 54% clinicians advised OCT after 5 years (47.5%) or formal ophthalmology monitoring(6.5%) in line with published international guideline. Barriers to following required pretreat- ment tests and monitoring we noted from this survey include lack of awareness or disagreement with guidelines (lack of conclusive data), doubtful cost effectiveness and nonadherence by patients due to cost implications.

Conclusion: There is need to improve awareness of existing evidence based guidelines on prescription and monitoring of Hydroxychloroquine by international ophthalmology and rheumatology organizations. There is more data needed to prove effectiveness of current guidelines beyond doubt. We also need to better counsel and educate patients on the drug so adherence can be improved.

REFERENCES

Disclosure of Interests: Shilpa Jagadeesh : None declared, Arumugam Moorthy Spokes bureau: Speaker fee from Abbvie, Novartis., B G Dharmanand: None declared


CHECKING IN WITH IMMUNE CHECKPOINT INHIBITORS: RESULTS FROM A NEEDS ASSESSMENT SURVEY OF CANADIAN RHEUMATOLOGISTS

Ahmad Abdullah¹, Nancy Maltez², Marie Hudson¹, Aurore Fili-Mah², Shahin Jamal². The Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO), ¹University of British Columbia, Rheumatology, Vancouver, Canada; ²University of Ottawa, Rheumatology, Ottawa, Canada; 3McGill University, Montreal, Canada; 4University of Calgary, Calgary, Canada; 5University of British Columbia, Vancouver, Canada

Background: Immune checkpoint inhibitors (ICI) have revolutionized the treatment of cancer. However, enhanced immune activation from ICI has been associated with immune-related adverse events (irAE), including autoimmune rheumatologic diseases such as inflammatory arthritis, spondyloarthropathy, polymyalgia rheumatica-like syndrome and inflammatory myositis, among many others. This emerging field represents a challenge given that experience with these conditions is limited and evidence-based recommendations do not yet exist.

Objectives: The Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO) is an emerging network of rheumatologists interested in rheumatic irAE (rh-irAE). CanRIO undertook a needs assessment survey to understand the need for education and recommendations for the management of rh-irAE in the rheumatology community in Canada. The primary objective was to recognize the knowledge gaps, if any, and understand current patterns of practice in this newly emerging area.

Methods: A 25-item electronic survey was developed by the CanRIO investigators. The survey, which was available in both French and English, was distributed via electronic mail to 574 members of the Canadian Rheumatology Association (CRA). Responses were collected over a period of 14 days. Results were summarized using descriptive statistics.

Results: Of the 574 CRA members who were invited to participate, 83 responded (response rate of 14.5%). Half of the respondents were adult rheumatologists from academic centres and 26% from the community. Over 25% of the respondents were not familiar with ICI and irAE. Half of the respondents had not seen or managed patients with irAE, and among the remaining, the majority had seen less than 5 patients with irAE. Inflammatory arthritis was the most common rh-irAE encountered. Other rh-irAE included sicca, myositis, sarcoid and vasculitis. Prednisone and corticosteroids were the most common treatment strategies. Almost half of the respondents (43.6%) had been asked for advice from oncologists regarding discontinuation of ICI for irAE, and of these, almost half (48.7%) reported that they were either ‘slightly confident’ or ‘not confident at all’ in providing advice. Overall, half of the respondents had not yet been asked to provide advice concerning ICI for patients with pre-existing auto-immune diseases. The vast majority (87.2%) agreed that there was a need for clinical practice guidelines for the management of rh-irAE.

Conclusion: The survey highlighted the important knowledge gaps in the emerging field of rh-irAE. Given the increasing use of ICI in a growing number of cancer types and stages, referrals for rh-irAE are likely to increase. There is strong rationale to develop educational programs and clinical practice guidelines to support Canadian rheumatologists who will be increasingly responsible for managing rh-irAE.

REFERENCE

Disclosure of Interests: Ahmad Abdullah: None declared, Nancy Maltez: None declared, Marie Hudson Grant/research support from: Unrestricted research funds from Bristol-Myers Squibb, Aurore Fili-Mah Grant/research support from: Roche, Abbvie, Janssen, BMS, Speakers bureau: Roche, Abbvie, Janssen, BMS, Pfizer, Shahin Jamal Consultant for: Consultant for Abbvie, Amgen, BMS, Eli Lilly, Pfizer, Janssen, Merck, UCB


WHY DO PATIENTS CLAIM? ANALYSIS OF THE CLAIMS MADE BY PATIENTS THROUGH CUSTOMER SERVICE

Enrique Judez Navarro 1, Carlos Sánchez-Piedra 2, Gines Sanchez Nievas 2, Isabel Labiano 3, Manuela Sines 3, Gloria García Consuegra 3, Sandra Soro 3, M Angeles García Morales 3, ¹Complejo Hospitalario Universitario de Albacete, Rheumatology, Albacete, Spain; ²Spanish Society of Rheumatology (SER), Madrid, Spain

Background: Analysis of the claims made by patients could be an indicator of quality and show strengths and aspects of improvement in the organization of a rheumatology department.

Objectives: The aims of the present study are to evaluate these claims, describe the sociodemographic and clinical characteristics of claiming patients and to determine the association between medical history and types of complaints.

Methods: Cross-sectional study. Claims made by patients treated by a rheumatology department between 04/2016 and 12/2017 were analyzed. A descriptive analysis of these claims was carried out followed by a multivariate logistic regression model to determine the effect of the diagnosis of Fibromyalgia (FM)/Chronic Widespread Pain (CWP) on the type of claim and its association with clinical variables. A p <0.05 was consid- ered significant.
**Results:** One hundred and nine patients (mean age 54.7 ± 18.5 years, 78% women and 50.5% residents in rural areas) made 113 claims. The main reasons for claiming were: ‘advance medical evaluation and/or tests’ (45.1%), ‘request for evaluation by a specific physician’ (24.8%) and ‘rejection of evaluation by specific physician’ (13%, 3%). 67% of the claims were satisfied. The least satisfied claims were ‘request for evaluation by specific doctor’ (39.3%) while claims for ‘cancellation of evaluation’ were satisfied in 88% of the cases.

Median time between claim and previous medical visit was 99 [34-203] days and between claim and the subsequent medical consultation was 44 [28-82] days. Patients whose claims were due to ‘unpleasant attendance’ were the first to complaint (median 28 [2-72] days) but waited for the longest time to be attended (median 103 [46-147] days), ‘Cancellation of evaluation’ was attended after a median of 31.5 [28-33] days.

The main reasons for medical evaluation were: inflammatory/rheumatic disease in 25 patients (22.15%), neck and low back pain in 23 patients (20.35%) and FM/CWP also in 20.35% of patients. As personal medical history, Psychiatric Disorders were present in 20.5% of patients and multiple comorbidities in 19.6% of patients. Twenty patients had no medical history of interest.

Regarding the type of claims, differences were observed related to the diagnosis and the patient’s medical history. The logistic regression model (FM dependent variable) adjusted for sex, age, rural area, time to/after the claim and medical history showed that patients with FM/CWP requested more frequently to “be evaluated by other physician” (OR of 23.92 [95% CI, 1.4-409.06] and “reject to be evaluated by a specific physician” (OR of 8.48 [95% CI, 1.2-60.09] than the rest of the patients and also, presented more frequently with psychiatric history (OR of 22.39 [95% CI, 1.15-437.23]).

**Conclusion:** The present study reflects main reasons for claiming of patients treated in a rheumatology department. Reasons of claiming and comorbidities of patients with FM/CWP differ from those of the rest of patients. These findings may be of interest for the organization of resources in rheumatology departments.

**Disclosure of Interests:** Enrique Judex Navarro Consultant for: Roche, Carlos Sánchez-Piedra: None declared, Gines Sanchez Nievas: None declared, Isabel Labiano: None declared, Manuela Sianes: None declared, Enrique Judez Navarro Consultant for: Roche, Disclosure of Interests: None declared.

---

**AB1218**

**ANALYSIS OF REFERRAL TRENDS TO A SECONDARY CARE RHEUMATOLOGY SERVICE FROM GENERAL PRACTICE OVER A TEN-YEAR PERIOD**

Ganesh Kasavkar, Kaushik Chaudhuri, Roxanne McVittie. University Hospital Coventry and Warwickshire, Rheumatology, Coventry, United Kingdom

**Background:** The practice of Rheumatology in the UK has undergone significant change in the past decade. These have been driven by developments in our understanding of the diseases; early arthritis clinics; developments in our understanding of the diseases; early arthritis clinics; introduction of the out-patient approach, and rheumatology training. All of these changes have been accompanied by a rise in the number of claims made for medical evaluation.

**Objectives:** The study was a retrospective analysis of claims for medical evaluation made to a general practice rheumatology service in the UK over a 10-year period (2006-2016). The study aimed to assess referral patterns and reasons for claiming between 2006 and 2016 and to identify changes in the referral process over this time.

**Methods:** Referral data was obtained from the primary care in the months of February 2006, August 2012 and February 2016. The main reason for claiming was ‘unpleasant attendance’ (67%), followed by ‘cancellation of evaluation’ (39.3%), and ‘request for evaluation by specific physician’ (39.3%). The least satisfied claims were ‘request for evaluation by specific doctor’ (39.3%) while claims for ‘cancellation of evaluation’ were satisfied in 88% of the cases.

**Conclusion:** The present study reflects main reasons for claiming of patients treated in a rheumatology department. Reasons of claiming and comorbidities of patients with FM/CWP differ from those of the rest of patients. These findings may be of interest for the organization of resources in rheumatology departments.

**Disclosure of Interests:** Enrique Judex Navarro Consultant for: Roche, Carlos Sánchez-Piedra: None declared, Gines Sanchez Nievas: None declared, Isabel Labiano: None declared, Manuela Sianes: None declared, Enrique Judez Navarro Consultant for: Roche, Disclosure of Interests: None declared.

---

**AB1219**

**EFFECTS OF A WORKPLACE-CENTERED COUNSELING OF INDIVIDUALS WITH MUSCULOSKELETAL COMPLAINTS: A PROSPECTIVE COHORT STUDY**

Harald Leiss,1 Miriam Hucke,2 Veronika Machold-Fabrizii,3 Josef S. Smolen1, Klaus Machold1,1 Medical University of Vienna, Department of Rheumatology, Vienna, Austria; 2Klinikum Klagenfurt, Department of Internal Medicine and Gastroenterology, Hepatology, Endocrinology and Nephrology, Klagenfurt, Austria; 3Wilhelminenspital, 6th Medical Department with Nephrology and Dialysis, Vienna, Austria

**Background:** Employed people with musculoskeletal complaints often seek medical advice when symptoms are chronic and lead to loss of workability.

**Objectives:** A brief examination was offered in the workplace setting to detect and to counsel individuals with symptoms of Rheumatic and musculoskeletal diseases (RMDs).

**Methods:** Employees received a questionnaire regarding musculoskeletal problems. In case of a positive screening, consultation by RMD specialists was offered. If necessary, participants were referred to a clinic specialized in RMDs. Employees’ work was categorized into physically-high-demanding (HD) and less-demanding (LD).

**Results:** 6170 employees were invited. 413 participated in the counseling program, 344 were enrolled in the study. 56.6% of the participants had no previously diagnosed RMD. After the specialists’ assessment, this percentage decreased to 37.5%. Men with LD-workload had significantly higher wellbeing (EQ-5D scale) compared to women with both LD (p=0.034) and HD (p=0.001). HD and LD differed significantly regarding percentage with painful upper (p=0.006) and lower (p=0.016) limbs. Back pain was distributed equally among all groups. HD women reported significantly higher use of NSAIDs (p=0.001). 235 individuals participated in telephone follow-up. There was significant improvement in wellbeing (p=0.006) and in rating of RMD pain (p=0.001). Participants who were suspected to suffer from RMDs had significantly increased out of pocket costs after one year (p=0.026). Use of NSAIDs decreased significantly from 29.1 to 17.4% (p=0.02). Rates of use of physiotherapy (p=0.001), gymnastics (p=0.001), physical therapy (p=0.027) and complementary/alternative methods (p=0.003) were significantly increased.

**Conclusion:** We found most physical/psychological problems related to RMDs in HD-working women. After one year, participants reported improved quality of life, reduction of RMD pain, higher utilization of medical services and of gymnastics, less use of NSAIDs, and, if suspected to suffer from RMDs, higher out of pocket costs. Thus, this workplace-centered intervention appears to have beneficial effects on both subjective well-being and physical/psychological health.

**Disclosure of Interests:** Harald Leiss Consultant for: Lilly, MSD, Miriam Hucke Grant/research support from: Abbvie, Veronika Machold-Fabrizii, Josef S. Smolen, Lilly, Janssen, MSD, Pfizer, Roche, Consultant for: AbbVie, Amgen, Astra-